Skip to main content
Fig. 4 | Cell Communication and Signaling

Fig. 4

From: Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Fig. 4

Evolutionary mechanism of drug resistance and targeted therapeutic strategies. Cell clones with primary EGFR activating mutations (e.g., L858R and ex19del mutation) appeared T790M resistant clones under the selection or induction of the 1st and 2nd generation TKIs. C797S resistant clones appeared under the same mechanism of 3rd generation TKIs. The two mutated genes, C797S and T790M, can be located on the same DNA strand (in cis) or on different DNA strands (in trans). There are now different effective therapeutic strategies for these specific combinations of drug-resistant mutations that have evolved from drug selection

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X